Mechanism of the inhibitory action of chestnut astringent skin extract on carbohydrate absorption

Journal of Nutritional Science and Vitaminology

Volumn 54, Issue 5, 2008, Pages 416-421

  Tsujita, Takahiro ^a   Takaku, Takeshi ^a  

^a EHIME UNIVERSITY   (Japan)

Author keywords

Amylase inhibitor; Blood glucose; Chestnut astringent skin; db db mice; Oral carbohydrate tolerance test

Indexed keywords

AESCULUS HIPPOCASTANUM EXTRACT; ALPHA GLUCOSIDASE; AMYLASE; GLUCOSE; MALTOSE; STARCH; SUCRASE; ASTRINGENT AGENT; CARBOHYDRATE; ENZYME INHIBITOR; PLANT EXTRACT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CARBOHYDRATE ABSORPTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; IC 50; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; ENZYMOLOGY; EXPERIMENTAL DIABETES MELLITUS; FAGACEAE; INTESTINE ABSORPTION; METABOLISM; NONOBESE DIABETIC MOUSE; NUT; PLANT EPIDERMIS;

MUS; RATTUS;

ALPHA-AMYLASES; ALPHA-GLUCOSIDASES; ANIMALS; AREA UNDER CURVE; ASTRINGENTS; BLOOD GLUCOSE; BODY WEIGHT; CARBOHYDRATES; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FAGACEAE; INTESTINAL ABSORPTION; MALE; MICE; MICE, INBRED NOD; NUTS; PLANT EPIDERMIS; PLANT EXTRACTS; RATS; SUCRASE;

EID: 63849267393     PISSN: 03014800     EISSN: 18817742     Source Type: Journal    
DOI: 10.3177/jnsv.54.416     Document Type: Article

References (23)

1. Bischoff H. 1994. Pharmacology of alpha-glucosidase inhibition. Eur J Clin Invest 24: S3-S10.
2. Peterson RG. 1994. Alpha-glucosidase inhibition in diabetes: lessons from animal studies. Eur J Clin Invest 24: S11-S18.
3. Horii S, Fukase H, Matsuo T, Kameda Y, Asano N, Matsui K. 1986. Synthesis and alpha-D-glucosidase activity of N-substituted valioamine derivatives as potential oral antidiabetic agents. J Med Chem 29: 1038-1046.
4. Matsuo T, Odaka H, Ikeda H. 1992. Effect of an intestinal disaccharidase inhibitor (AO-128) on obesity and diabetes. Am J Clin Nutr 55: 314S-317S.
5. DeFronzo RA. 1999. Pharmacologic theraphy for type 2 diabetes mellitus. Ann Intern Med 131: 281-303.
6. Goto Y, Yamada K, Ohyama T, Matsuo T, Odaka H, Ikeda H. 1995. An alpha-glucosidase inhibitor, AO-128, retards carbohydrate absorption in rats and humans. Diabetes Res Clin Pract 28: 81-87.
7. O'Donnell MD, McGeeney KF. 1976. Purification and properties of an alpha-amylase inhibitor from wheat. Biochim Biophys Acta 422: 159-169.
8. Oneda H, Lee S, Inouye K. 2004. Inhibitory effect of 0.19 alpha-amylase inhibitor from wheat kernel on the activity of porcine pancreas alpha-amylase and its thermal stability. J Biochem 135: 421-427.
9. Tsujita T, Takaku T, Suzuki T. 2008. Chestnut astringent skin extract, an amylase inhibitor, retards carbohydrate absorption in rats and humans. J Nutr Sci Vitaminol 54: 82-88.
10. Kessler M, Acuto O, Storelli C, Murer H, Müler M, Semenza G. 1978. A modified procedure for the rapid preparation of efficiently transporting vesicles from small intestinal brush border membranes. Their use in investigating some properties of D-glucose and choline transport systems. Biochim Biophys Acta 506: 136-154.
11. Dahlqvist A. 1964. Method for assay of intestinal disaccharidases. Anal Biochem 7: 18-2 5.
12. Miller GL. 1959. Use of dinitrosalicylic acid reagent for determination of reducing suger. Anal Chem 31: 426-428.
13. Tsujita T, Takaichi H, Takaku T, Aoyama S, Hiraki J. 2006. Antiobesity action of epsilon-polylysine, a potent inhibitor of pancreatic lipase. J Lipid Res 47: 1852-1858.
14. Yoon KH, Lee JH, Kim JW, Cho JH, Ko SH, Zimmet P. Son HY. 2006. Epidemic obesity and type 2 diabetes in Asia. Lancet 368: 1681-1688.
15. Bonora E, Muggeo M. 2001. Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: the epidemiological evidence. Diabetologia 44: 2107-2114.
16. Ceriello A. 2005. Postprandial hyperglycemia and diabetes complications. Is it time to treat? Diabetes 54: 1-7.
17. Yamagishi SI, Nakamura K, Matsui T, Ueda SI, Imaizumi T. 2007. Role of postprandial hyperglycemia in cardiovascular disease in diabetes. Int J Clin Pract 61: 83-87.
18. Koukiekolo R, Le Berre-Anton V, Desseaux V, Moreau Y, Rouge P, Marchis-Mouren G, Santimone M. 1999. Mechanism of porcine pancreatic alpha-amylase inhibition of amylose and maltopentaose hydrolysis by kidney bean (Phaseolus vulgaris) inhibitor and comparison with that by acarbose. Eur J Biochem 265: 20-26.
19. Lankisch M, Layer P, Rizza RA, DiMagno EE 1998. Acute postprandial gastrointestinal and metabolic effects of wheat amylase inhibitor (WAI) in normal, obese and diabetic humans. Pancreas 17: 176-181.
20. Layer P, Zinsmeister AR, DiMagno EP. 1986. Effect of decreasing intraluminal amylase activity on starch digestion and postprandial gastrointestinal function in human. Gastroenterology 91: 41-48.
21. Hummel KP, Dickie MM, Coleman DL. 1966. Diabetes, a new mutation in the mouse. Science 153: 1127-1128.
22. Kobayashi K, Forte TM, Taniguchi S, Ishida BY, Oka K, Chan L. 2000. The db/db mouse, a model for diabetic dyslipidemia: molecular characterization and effects of Western diet feeding. Metabolism 49: 22-31.
23. Coleman DL. 1978. Obese and diabetes: two mutant genes causing diabetes-obesity syndromes in mice. Diabetologia 14: 141-148.